Pretreatment with quercetin prevents changes in lymphocytes E-NTPDase/E-ADA activities and cytokines secretion in hyperlipidemic rats
Abstract Hyperlipidemia (HL) is a condition associated with endothelial dysfunction and inflammatory disorders. Purinergic system ectoenzymes play an important role in modulating the inflammatory and immune response. This study investigated whether the preventive treatment with quercetin is able to prevent changes caused by hyperlipidemia in the purinergic system, through the activities of E-NTPDase and E-ADA in lymphocytes, and quantify the nucleotides and nucleoside, and the secretion of anti- and proinflammatory cytokines. Animals were divided into saline/control, saline/quercetin 5 mg/kg, saline/quercetin 25 mg/kg, saline/quercetin 50 mg/kg, saline/simvastatin (0.04 mg/kg), hyperlipidemia, hyperlipidemia/quercetin 5 mg/kg, hyperlipidemia/quercetin 25 mg/kg, hyperlipidemia/quercetin 50 mg/kg, and hyperlipidemia/simvastatin. Animals were pretreated with quercetin for 30 days and hyperlipidemia was subsequently induced by intraperitoneal administration of 500 mg/kg of poloxamer-407. Simvastatin was administered after the induction of hyperlipidemia. Lymphocytes were isolated and E-NTPDase and E-ADA activities were determined. Serum was separated for the cytokines and nucleotide/nucleoside quantification. E-NTPDase and E-ADA activities were increased in lymphocytes from hyperlipidemic rats and pretreatment with quercetin was able to prevent the increase in the activities of these enzymes caused by hyperlipidemia. Hyperlipidemic rats when receiving pretreatment with quercetin and treatment with simvastatin showed decreased levels of ATP and ADP when compared to the untreated hyperlipidemic group. The IFN-γ and IL-4 cytokines were increased in the hyperlipidemic group when compared with control group, and decreased when hyperlipidemic rats received the pretreatment with quercetin. However, pretreatment with quercetin was able to prevent the alterations caused by hyperlipidemia probably by regulating the inflammatory process. We can suggest that the quercetin is a promising compound to be used as an adjuvant in the treatment of hyperlipidemia..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:444 |
|---|---|
| Enthalten in: |
Molecular and cellular biochemistry - 444(2017), 1-2 vom: 29. Nov., Seite 63-75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Braun, Josiane B. S. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s11010-017-3231-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR015658236 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR015658236 | ||
| 003 | DE-627 | ||
| 005 | 20230519121348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201006s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11010-017-3231-6 |2 doi | |
| 035 | |a (DE-627)SPR015658236 | ||
| 035 | |a (SPR)s11010-017-3231-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q ASE |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Braun, Josiane B. S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pretreatment with quercetin prevents changes in lymphocytes E-NTPDase/E-ADA activities and cytokines secretion in hyperlipidemic rats |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Hyperlipidemia (HL) is a condition associated with endothelial dysfunction and inflammatory disorders. Purinergic system ectoenzymes play an important role in modulating the inflammatory and immune response. This study investigated whether the preventive treatment with quercetin is able to prevent changes caused by hyperlipidemia in the purinergic system, through the activities of E-NTPDase and E-ADA in lymphocytes, and quantify the nucleotides and nucleoside, and the secretion of anti- and proinflammatory cytokines. Animals were divided into saline/control, saline/quercetin 5 mg/kg, saline/quercetin 25 mg/kg, saline/quercetin 50 mg/kg, saline/simvastatin (0.04 mg/kg), hyperlipidemia, hyperlipidemia/quercetin 5 mg/kg, hyperlipidemia/quercetin 25 mg/kg, hyperlipidemia/quercetin 50 mg/kg, and hyperlipidemia/simvastatin. Animals were pretreated with quercetin for 30 days and hyperlipidemia was subsequently induced by intraperitoneal administration of 500 mg/kg of poloxamer-407. Simvastatin was administered after the induction of hyperlipidemia. Lymphocytes were isolated and E-NTPDase and E-ADA activities were determined. Serum was separated for the cytokines and nucleotide/nucleoside quantification. E-NTPDase and E-ADA activities were increased in lymphocytes from hyperlipidemic rats and pretreatment with quercetin was able to prevent the increase in the activities of these enzymes caused by hyperlipidemia. Hyperlipidemic rats when receiving pretreatment with quercetin and treatment with simvastatin showed decreased levels of ATP and ADP when compared to the untreated hyperlipidemic group. The IFN-γ and IL-4 cytokines were increased in the hyperlipidemic group when compared with control group, and decreased when hyperlipidemic rats received the pretreatment with quercetin. However, pretreatment with quercetin was able to prevent the alterations caused by hyperlipidemia probably by regulating the inflammatory process. We can suggest that the quercetin is a promising compound to be used as an adjuvant in the treatment of hyperlipidemia. | ||
| 650 | 4 | |a Flavonoid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cholesterol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ectoenzymes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytokines |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ruchel, Jader B. |e verfasserin |4 aut | |
| 700 | 1 | |a Manzoni, Alessandra G. |e verfasserin |4 aut | |
| 700 | 1 | |a Abdalla, Fátima H. |e verfasserin |4 aut | |
| 700 | 1 | |a Casalli, Emerson A. |e verfasserin |4 aut | |
| 700 | 1 | |a Castilhos, Lívia G. |e verfasserin |4 aut | |
| 700 | 1 | |a Passos, Daniela F. |e verfasserin |4 aut | |
| 700 | 1 | |a Leal, Daniela B. R. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular and cellular biochemistry |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1973 |g 444(2017), 1-2 vom: 29. Nov., Seite 63-75 |w (DE-627)SPR015608352 |w (DE-600)2003615-2 |x 1573-4919 |7 nnns |
| 773 | 1 | 8 | |g volume:444 |g year:2017 |g number:1-2 |g day:29 |g month:11 |g pages:63-75 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11010-017-3231-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q ASE |
| 951 | |a AR | ||
| 952 | |d 444 |j 2017 |e 1-2 |b 29 |c 11 |h 63-75 | ||